RE:SNL "Blocking it out for Christmas" Tribute to Roche Wine"Roche’s leadership shuffle continued on Monday with the departure of pharma sector CEO Bill Anderson.
Anderson, formerly the boss of Roche subsidiary Genentech, took over as pharma CEO in 2019. But this year, the sector’s fortunes declined with several clinical setbacks. Anderson is leaving at the end of this year to “pursue other opportunities,” the company said in a release."
"This year has brought a series of developmental disappointments for Roche in biopharma. A month ago, Roche’s Alzheimer’s antibody gantenerumab failed in a pair of phase 3 trials. In May, Roche revealed a second phase 3 failure for lung cancer hopeful tiragolumab."
[ These developments could significantly benefit ONCY in any negotiations given Roche's erupting dependency on M&A to support its threatened product pipeline - as I posted several months ago ]
https://www.fiercepharma.com/pharma/another-leadership-change-roche-anderson-departs-pharma-sector-ceo